LLY

#11
Eli Lilly and Company Common Stock
1074.1 0 USD
-2.83%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
1 073.01
1 076.49
Range Annuel
644.51
1 149.10
Changement quotidien
-2.83%
Changement Mensuel
+12.08%
Evolution sur 6 mois
+2.02%
Changement Annuel
+46.20%
Clôture Précédente
1105.3 7
Open
1075.0 2
Low
1073.0 1
High
1076.4 9
Volume
150
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques Dividendes
Trimestriel Annuel
  • Market Capitalization 1.01 T
  • Employee 50 K
  • Founded N/A
  • CEO David A. Ricks
  • Website www.lilly.com
  • Headquarter Indiana, United States
  • FIGI BBG000BNBDC2
  • Industry Fabricants de Médicaments — Généralités
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
46.83
ratio cours/chiffre d'affaires
14.83
Dividende par action
6.23
Rendement du dividende (%)
0.58

Eli Lilly and Company Common Stock

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes.

Nouvelles